On October 22, 2020 Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, reported it will release its third quarter 2020 financial results after the market closes on Thursday, November 5, 2020 (Press release, Personalis, OCT 22, 2020, View Source [SID1234568867]). In conjunction with the release, the Company will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Interested parties may access the live call via telephone by dialing (866) 220-8061 for domestic callers or (470) 495-9168 for international callers, using conference ID: 9697771. The live webinar of the call may be accessed by visiting the Events section of the company’s website at investors.personalis.com. A replay of the webinar will be available shortly after the conclusion of the call and will be archived on the company’s website.

On October 22, 2020 RefleXion Medical, a therapeutic oncology company pioneering biology-guided radiotherapy* (BgRT) as a new modality for treating all stages of cancer, reported that eight clinical abstracts evaluating the use of its novel technology were accepted for presentation during the virtual American Society for Radiation Oncology (ASTRO) 2020 Annual Meeting, Oct. 24-28 (Press release, RefleXion Medical, OCT 22, 2020, View Source [SID1234568866]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are thrilled to have eight abstracts from leading academic clinicians highlighting our technology," said Sean Shirvani, M.D., senior vice president of Clinical and Medical Affairs at RefleXion. "The presentations will share new data on the potential of BgRT for targeting tumors in diverse anatomic locations and from varied histologies, including non-small cell lung, prostate and pancreatic cancers. The investigations also explore the exciting opportunity of leveraging PET information as a future biomarker with BgRT.

"Through our clinical partnerships, we continue to produce comprehensive, evidence-based research that builds on the strong foundation of previously published studies," continued Shirvani. "We believe the RefleXion X1 can form the backbone of any radiotherapy clinic, as it delivers IMRT/SBRT/SRS and unlocks opportunities for procedural growth with BgRT in local and metastatic disease."

The following presentations taking place during ASTRO 2020 evaluate RefleXion’s novel technology:

Sunday, Oct 25, 2:15 PM. Poster Session 02, Poster Hall:

2686 "Simultaneous Integrated Boost of Lung Tumors in the Stereotactic Ablative Setting using BgRT Tracked Delivery"
2831 "Use of a Detailed Process Map for Clinical Workflow of a New Biology-guided Radiotherapy (BgRT) Machine"
2768 "Feasibility of Biology-Guided Radiotherapy for Pancreatic Tumors: An Assessment of Normalized Target SUV"
Monday, Oct 26, 12:20 PM Physics 06 – Imaging and Response Assessment:

SS 21 – "Increased 18F-FDG Metabolic Activity During Lung SBRT Predicts Risk of Disease Progression: Results from a Prospective Study of Serial Inter-Fraction PET/CTs"
Tuesday, Oct 27:

3:15 PM QP-19 – Physics – Motion Management "Feasibility of Biology-guided Radiotherapy (BgRT) Targeting FDG Avid Liver Metastases"
2:00 PM 2268 PV 06 Poster "FDG-PET Metrics in Advanced Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-Analysis"
2:00 PM 2258 PV 06 Poster "Prognostic Value of FDG-PET Metrics for Advanced NSCLC Patients Treated with First-line Immunotherapy"

On October 22, 2020 The Mary Kay Foundation℠ recently reported that awarded $1 million in grants to ten researchers on the frontline battling cancers that primarily affect women (Press release, The Mary Kay Foundation, OCT 22, 2020, View Source [SID1234568865]). The grants, which benefit institutions in Mary Kay’s home state of Texas all the way to Wisconsin and New York, are part of The Mary Kay Foundation’s annual cancer research grant cycle, totaling nearly $24 million since inception.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

After reviewing more than 75 applications, The Mary Kay Foundation Research Review Committee awarded $100,000 grants to 10 accredited cancer research institutions. This year’s grant recipients include:

Beckman Research Institute of City of Hope
Columbia University Irving Medical Center
NYU Grossman School of Medicine
Stanford University School of Medicine
The University of Texas Health Science Center at San Antonio
University of California San Diego
UT Southwestern Medical Center
The University of Tennessee Health Science Center
University of Virginia
University of Wisconsin School of Medicine and Public Health
"The Mary Kay Foundation has a two-fold mission: to end gender-based violence and empower researchers to find cures for cancers that primarily affect women," said Michael Lunceford, President of The Mary Kay Foundation Board of Directors. "Over the past several decades, our research grants have enabled some of the country’s top medical minds to make breakthroughs in treatments that we’re so proud of. Our hope—and belief—is that this year’s grantees will continue that inspiring research trend."

That research includes innovative studies from scientists like Dr. Hua Yu, Associate Chair and Professor in the Department of Immuno-Oncology at the Beckman Research Institute of City of Hope. Dr. Yu will use the grant provided by The Mary Kay Foundation to study the opposing roles of PARP and PARG inhibitors in regulating ovarian cancer immune responses. Dr. Paul Lambert, Howard M. Temin Professor and Chair of Oncology at the University of Wisconsin Schools of Medicine and Public Health, will use the funds to research the role of human’s microbiome in cervical cancer. In New York, Dr. Alberto Ciccia, Assistant Professor of Genetics & Development at Columbia University Medical Center, will use the funds to study large-scale functional analysis of BRCA1/2 single nucleotide variants.

"By offering continued support for these scientists and institutions," added Lunceford, "we are continuing Mary Kay’s ultimate goal, which is to better the lives of women everywhere."

On October 22, 2020 bioAffinity Technologies, a privately held biotech company, reported its poster "Automated Flow Cytometry Test Distinguishes Cancer from Non-Cancer in Sputum with High Sensitivity and Specificity" has been accepted for presentation at the International Association for the Study of Lung Cancer (IASLC) 2020 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer, Singapore, Worldwide Virtual Event (WCLC 2020) from Jan. 28 to 31, 2021 (Press release, BioAffinity Technologies, OCT 22, 2020, View Source [SID1234568864]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

bioAffinity Technologies will present results of its test validation trial for CyPath Lung, a non-invasive test for the early detection of lung cancer, that evaluated the test’s ability to distinguish people at high risk for lung cancer from high-risk patients with the disease. The test validation trial resulted in CyPath Lung specificity of 88% and sensitivity of 82%, similar to far more invasive procedures currently used to diagnose lung cancer. CyPath Lung performed even better, with 92% sensitivity and 87% specificity, in the group of cancer and cancer-free high-risk participants who had no nodules or small nodules less than 2 cm in diameter.

The WCLC is the world’s largest international gathering of clinicians, researchers and scientists in the field of lung cancer and thoracic oncology, according to the conference website. The poster, #3394, will be available to participants of the WCLC 2020 on the Virtual Event Forum beginning Jan. 28 as part of Session P07 – Early Stage/Localized Disease.

On October 22, 2020 Asana BioSciences, a clinical stage biopharmaceutical company, reported that ASN007 clinical data on safety, efficacy and pharmacokinetics in solid tumor patients will be presented at the 32nd EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Virtual Symposium on Molecular Targets and Cancer Therapeutics (ENA 2020) to be held on October 24-25, 2020 (Press release, Asana BioSciences, OCT 22, 2020, View Source [SID1234568862]). Details of this invited presentation are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Title: Targeting ERK with novel inhibitor ASN007

Presenter: Filip Janku, MD, PhD. Associate Professor, Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center

Session Title: New Drugs on the Horizon

Date and Time: Sunday, October 25, 2020 at 21:00 CET/4:00 PM US ET

About ASN007

ASN007 is an orally bioavailable, potent and selective inhibitor of ERK1/2 designed to potently inhibit the RAS/RAF/MEK/ERK (MAPK) signaling pathway. ASN007 shows potent preclinical activity in KRAS-driven models, irrespective of subtype mutation, and in BRAF mutant models, including RAF/MEK inhibitor-resistant melanoma. ASN007 has a long target residence time and shows activity in preclinical models using an intermittent dosing schedule. ASN007 has been evaluated in patients with advanced solid tumors, including BRAF- and KRAS-mutant cancers (NCT03415126). The maximum tolerated dose levels (MTD) and recommended Phase 2 dose (RP2D) has been determined. Clinical development of ASN007 is ongoing and aims to address the medical need across a range of cancer types defined by RAS/RAF/MEK driven mutations as monotherapy and in combinations.